Pfizer Inc. and BioNTech SE said the Covid-19 vaccine they are jointly developing is on track to be submitted for regulatory review as early as October, as they released additional data from an early-stage study.
The companies said the vaccine was well tolerated with mild to moderate fever in fewer than 20% of the participants. The companies are continuing to analyze data from the Phase 1 trials in the U.S. and Germany, they said in a statement.
The confirmation of their October goal, first announced last month, helped lift S&P 500 futures early on Friday as part of a drumbeat of positive news on inoculation efforts that have the potential to end the threat of damaging lockdowns.
Subscribe to The Capsule, a daily brief monitoring advances in health care and biopharma, delivered free to your inbox.
The timeline would make the vaccine one of the fastest-moving in the world. Some analysts expect a vaccine to be approved for use by November in the U.S., a move which may give President Donald Trump a new foothold in the election.
Pfizer and BioNTech last month clinched a $2 billion deal to supply an initial 100 million doses of the vaccine to the U.S. Governments around the world are looking to lock up supplies of still-experimental candidates in hope of stabilizing local economies and stopping spread of the virus that’s taken almost 800,000 lives globally.
More coronavirus coverage from Fortune:
- WHO chief warns the world: Don’t fall prey to COVID “vaccine nationalism”
- What makes the latest coronavirus testing process, developed by Yale, so promising
- Commentary: Why empowering frontline workers is a key element to a safe reopening
- Urinals and toilets may spread COVID-19, adding fuel to the mask debate
- Depression symptoms among the employed in the U.K. have more than doubled since the start of the pandemic